Skip to Content

Ethionamide Disease Interactions

There are 4 disease interactions with ethionamide:

Major

Ethionamide (applies to ethionamide) hepatotoxicity

Major Potential Hazard, High plausibility. Applicable conditions: Diabetes Mellitus, Liver Disease, Alcoholism

The use of ethionamide is contraindicated in patients with severe liver damage. Like many other antituberculous agents, ethionamide is hepatotoxic. Transient elevations in bilirubin and serum SGOT (AST) and SGPT (ALT) have been reported in 5% of the patients treated with ethionamide. Hepatitis, with or without jaundice, has also been observed, particularly in patients with diabetes mellitus. Therapy with ethionamide should be administered cautiously in patients with liver disease, a history of alcoholism, or diabetes. Liver function tests should be measured at baseline and monthly during therapy, and ethionamide withdrawn at the first signs or symptoms suggestive of liver damage.

References

  1. Mandell GL, Bennett JE, Dolin R, eds.. "Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed." New York, NY: Churchill Livingston 1 (1995):
  2. "Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Major

Ethionamide (applies to ethionamide) liver disease

Major Potential Hazard, High plausibility.

Ethionamide is primarily metabolized by the liver. Patients with liver disease may be at greater risk for adverse effects from ethionamide due to decreased drug clearance. Dosage reductions are recommended in these patients.

References

  1. "Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Major

Ethionamide (applies to ethionamide) peripheral neuropathy

Major Potential Hazard, Low plausibility. Applicable conditions: Alcoholism, Malnourished, Diabetes Mellitus

Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent. Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism. Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.

References

  1. "Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Moderate

Ethionamide (applies to ethionamide) diabetes mellitus

Moderate Potential Hazard, Moderate plausibility.

The use of ethionamide has occasionally been associated with poor diabetic control. Patients with diabetes mellitus should be monitored more closely during therapy with ethionamide, and their antidiabetic regimen adjusted accordingly.

References

  1. "Product Information. Trecator-SC (ethionamide)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. Mandell GL, Bennett JE, Dolin R, eds.. "Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed." New York, NY: Churchill Livingston 1 (1995):

Ethionamide drug interactions

There are 135 drug interactions with ethionamide

Ethionamide alcohol/food interactions

There is 1 alcohol/food interaction with ethionamide

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.